RenovoRx Patents

Patent portfolio assigned to RenovoRx (verified via public assignee records). Estimated patent count: 3. Nasdaq-listed (RNXT) precision-oncology company; TAMP/RenovoCath locoregional drug delivery. Patents confirmed via Google Patents assignee RenovoRx Inc (US10695543B2 'Methods for treating cancerous tumors'; US20160015948A1 pancreas delivery devices; ES2828722T3). Competitors TriSalus (TriNav) and Delcath (CHEMOSAT/HEPZATO) are same-space locoregional delivery players. As a drug/device developer it has physician purchasers but no individually named end customers disclosed.